TAK Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

18.590

Open

18.220

VWAP

18.43

Vol

4.95M

Mkt Cap

58.51B

Low

18.180

Amount

91.14M

EV/EBITDA(TTM)

10.43

Total Shares

3.16B

EV

13.11T

EV/OCF(TTM)

12.22

P/S(TTM)

2.00

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.

Show More

Events Timeline

(ET)

2026-03-29

11:00:00

Takeda Announces New Data on Zasocitinib

2026-03-02 (ET)

2026-03-02

05:30:00

Takeda and Protagonist Therapeutics New Drug Application Accepted by FDA for Priority Review

2026-02-23 (ET)

2026-02-23

08:10:00

Boston Scientific Appoints New Board Members

2026-02-19 (ET)

2026-02-19

12:10:00

Takeda Announces Key Trial Data for ENTYVIO

2026-02-10 (ET)

2026-02-10

05:30:00

Takeda's New Drug Application Accepted by FDA for Priority Review

2026-01-29 (ET)

2026-01-29

05:40:00

Takeda Raises FY25 Revenue Outlook to ¥4.53B

News

Newsfilter

03-31Newsfilter

Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion

CNBC

Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion

NASDAQ.COM

03-29NASDAQ.COM

Takeda Reports Promising Phase 3 Data for Zasocitinib in Psoriasis

Newsfilter

03-28Newsfilter

Zasocitinib Shows Significant Efficacy in Psoriasis Studies

Yahoo Finance

03-28Yahoo Finance

Zasocitinib Shows Significant Efficacy in Psoriasis Studies

seekingalpha

03-25seekingalpha

Takeda Plans Over ¥200B in Annual Savings by 2028

1 Analyst Rating

Wall Street analysts forecast TAK stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

18.00

Averages

18.00

High

18.00

Current: 0.000

Low

18.00

Averages

18.00

High

18.00

H.C. Wainwright

H.C. Wainwright

Buy

maintain

$97

AI Analysis

2025-12-30

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

$97

AI Analysis

2025-12-30

maintain

Buy

Reason

H.C. Wainwright says Xoma (XOMA) took "a nice ride down the creativity road again with nice pipeline expansion," after the company announced an expanded relationship with partner Takeda (TAK). The deal with Takeda is highlighted by no cash out from Xoma for bringing in nine assets, the firm notes. This was accomplished by only marginally reducing Xoma's royalty/milestone share in Takeda's mezagitamab. Wainwright maintains its positive view here on the depth and breadth of Xoma's partnered assets as well as the ongoing creativity of transaction the company consummates, and looks forward to a transactional and royalty growing 2026. The firm has a Buy rating on Xoma with a price target of $97 on the shares.

JPMorgan

Neutral

maintain

$34 -> $35

2025-09-09

Reason

JPMorgan

Price Target

$34 -> $35

2025-09-09

maintain

Neutral

Reason

JPMorgan raised the firm's price target on Alkermes (ALKS) to $35 from $34 and keeps a Neutral rating on the shares. The firm sees see alixorexton as well-positioned in narcolepsy type I based on detailed results from the Phase II Vibrance-1 study. Alixorexton delivered a profile broadly inline with expectations with efficacy that generally looks better than Takeda's (TAK) Phase III data for oveporexton, the analyst tells investors in a research note. JPMorgan upped its probability of sucess for alixorexton in narcolepsy type I to 75% from 70% following the data.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TAK

Unlock Now

Valuation Metrics

The current forward P/E ratio for Takeda Pharmaceutical Co Ltd (TAK.N) is 0.00, compared to its 5-year average forward P/E of 27.52. For a more detailed relative valuation and DCF analysis to assess Takeda Pharmaceutical Co Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

27.52

Current PE

0.00

Overvalued PE

40.59

Undervalued PE

14.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

9.40

Current EV/EBITDA

9.87

Overvalued EV/EBITDA

10.58

Undervalued EV/EBITDA

8.21

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

1.57

Current PS

1.41

Overvalued PS

1.70

Undervalued PS

1.43

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what stocks to buy today by swing max

Intellectia · 30 candidates

Region: USPrice: $5.00 - $150.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Week Predict Return: >= 5.0%Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

Bright Horizons Family Solutions Inc

4.21B

Greenlight Capital Re Ltd

563.79M

BRC Group Holdings Inc

214.47M

Box Inc

3.37B

Fortis Inc

29.71B

NetEase Inc

75.69B

ANY STOCK FROM 5 TO 20.00

Intellectia · 1059 candidates

Region: USPrice: $5.00 - $20.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Mitsubishi UFJ Financial Group Inc

202.67B

Banco Santander SA

185.79B

Mizuho Financial Group Inc

105.35B

Petroleo Brasileiro SA Petrobras

92.03B

Itau Unibanco Holding SA

91.41B

Nu Holdings Ltd

87.41B

us stock between $0.1 and $20

Intellectia · 2503 candidates

Price: $0.10 - $20.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Mitsubishi UFJ Financial Group Inc

206.98B

Banco Santander SA

178.90B

Mizuho Financial Group Inc

104.37B

Petroleo Brasileiro SA Petrobras

87.06B

Itau Unibanco Holding SA

86.67B

Nu Holdings Ltd

83.54B

show stock below $20 and are marked bullish

Intellectia · 1002 candidates

Price: <= $20.00Option Sentiments: Bullish

Ticker

Name

Market Cap$

Lloyds Banking Group PLC

81.38B

Energy Transfer LP

60.60B

Takeda Pharmaceutical Co Ltd

51.17B

Banco Santander Brasil SA

50.00B

ASE Technology Holding Co Ltd

41.24B

Nokia Oyj

35.71B

acciones por debajo 20 dolares

Intellectia · 3008 candidates

Price: <= $20.00

Ticker

Name

Market Cap$

Mitsubishi UFJ Financial Group Inc

206.98B

Banco Santander SA

178.90B

Mizuho Financial Group Inc

104.37B

Petroleo Brasileiro SA Petrobras

87.06B

Itau Unibanco Holding SA

86.67B

Nu Holdings Ltd

83.54B

price between 1 and 20

Intellectia · 2629 candidates

Price: $1.00 - $20.00

Ticker

Name

Market Cap$

Mitsubishi UFJ Financial Group Inc

206.98B

Banco Santander SA

178.90B

Mizuho Financial Group Inc

104.37B

Petroleo Brasileiro SA Petrobras

87.06B

Itau Unibanco Holding SA

86.67B

Nu Holdings Ltd

83.54B

any cheaper stocks for option strategies

Intellectia · 1234 candidates

Price: <= $20.00Weekly Average Turnover: >= 1,000,000Is Optionable: True

Ticker

Name

Market Cap$

Mitsubishi UFJ Financial Group Inc

206.98B

Banco Santander SA

178.90B

Mizuho Financial Group Inc

104.37B

Petroleo Brasileiro SA Petrobras

87.06B

Itau Unibanco Holding SA

86.67B

Nu Holdings Ltd

83.54B

cheap stocks that are safe to daytrade

Intellectia · 54 candidates

Price: <= $20.00Relative Vol: >= 1.50Beta: LowRiskWeekly Average Turnover: >= 1,000,000Is Optionable: True

Ticker

Name

Market Cap$

Petroleo Brasileiro SA Petrobras

87.06B

Itau Unibanco Holding SA

86.67B

Vale SA

66.46B

Takeda Pharmaceutical Co Ltd

51.17B

Banco Santander Brasil SA

50.00B

Banco Bradesco SA

39.45B

top 10 bullish stocks under $30.00

Intellectia · 364 candidates

Price: <= $30.00Relative Vol: >= 1.50Rsi 14: >= 50Moving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

Petroleo Brasileiro SA Petrobras

87.06B

Itau Unibanco Holding SA

86.67B

Nu Holdings Ltd

83.54B

Vale SA

66.46B

Takeda Pharmaceutical Co Ltd

51.17B

Banco Santander Brasil SA

50.00B

Stocks ROI < 30%, calls 5x more than puts

Intellectia · 1148 candidates

Return On Equity: <= 30.0%Option Sentiments: Bullish

Ticker

Name

Market Cap$

Banco Bilbao Vizcaya Argentaria SA

141.76B

Sumitomo Mitsui Financial Group Inc

133.35B

Medtronic PLC

128.57B

ICICI Bank Ltd

104.54B

Slb NV

72.49B

American Electric Power Company Inc

63.55B

Whales Holding TAK

Trading Trends

People Also Watch

Frequently Asked Questions

What is Takeda Pharmaceutical Co Ltd (TAK) stock price today?

The current price of TAK is 18.52 USD — it has increased 1.37

What is Takeda Pharmaceutical Co Ltd (TAK)'s business?

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research, development, manufacturing and global sales of a wide range of pharmaceuticals. Its main business areas are divided into six, including gastroenterology, rare diseases, plasma-derived therapies, oncology (cancer), vaccines, and neuroscience (neuropsychiatric disorders). In research and development, the Company focuses on three priority disease areas, including gastroenterology and inflammatory diseases, neuroscience, and oncology, and also focuses on plasma-derived therapies.

What is the price predicton of TAK Stock?

Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Takeda Pharmaceutical Co Ltd (TAK)'s revenue for the last quarter?

Takeda Pharmaceutical Co Ltd revenue for the last quarter amounts to 1.19T USD, increased 4.16

What is Takeda Pharmaceutical Co Ltd (TAK)'s earnings per share (EPS) for the last quarter?

Takeda Pharmaceutical Co Ltd. EPS for the last quarter amounts to 65.65 USD, increased 337.08

How many employees does Takeda Pharmaceutical Co Ltd (TAK). have?

Takeda Pharmaceutical Co Ltd (TAK) has 47455 emplpoyees as of April 01 2026.

What is Takeda Pharmaceutical Co Ltd (TAK) market cap?

Today TAK has the market capitalization of 58.51B USD.